{
    "relation": [
        [
            "SYM",
            "AMPE",
            "ITMN",
            "OHRP",
            "AAPL",
            "FB"
        ],
        [
            "TRADE IT",
            "",
            "",
            "",
            "",
            ""
        ],
        [
            "LAST",
            "$2.59",
            "$73.89",
            "$3.11",
            "$121.65",
            "$95.85"
        ],
        [
            "%CHG",
            "-0.38%",
            "-0.03%",
            "1.60%",
            "-0.59%",
            "0.67%"
        ]
    ],
    "pageTitle": "Biotech Stock Mailbag: InterMune, Ohr Pharma, Ampio - TheStreet",
    "title": "",
    "url": "http://www.thestreet.com/story/12361371/1/biotech-stock-mailbag-intermune-ohr-pharma-ampio.html?kval=dontmiss",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 0,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988308.23/warc/CC-MAIN-20150728002308-00275-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 763057271,
    "recordOffset": 763018352,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampBeforeTable": "{14930=And if the nintedanib phase III studies are positive, why did BI start another phase III study last November using an unconventional primary endpoint?, 14642=We'll have to wait until May for answers, unless more data leak., 16542=.@Boehringer does not support publication of INPULSIS IPF data before ATS in May. We are committed to confidentiality & data protocols., 10806=Access the tool that DOMINATES the Russell 2000 and the S&P 500., 19042=The sharp selloff on Jan. 31 was caused by an article from BioPharm Insight, a subscription-based research/news service catering to investment fund managers and hedge funds, reporting positive results from two phase III studies of Boehringer's idiopathic pulmonary fibrosis (IPF) drug nintedanib. Boehringer (BI) has not reported data from the nintedanib studies. Biopharm obtained the data from an unnamed source described as being \"close to the situation.\", 16166=I've tried to get someone, anyone, at BI to explain what the hell happened, but the company isn't returning my phone calls or emails. In private conversations, the company is reportedly telling people the data from the nintedanib phase III studies won't be presented officially until the American Thoracic Society annual meeting in May. Until then, BI has no comment.}",
    "textBeforeTable": "Markets Today Stocks In Focus }; id: 12361371 TSCM.cfg.story = { var site_name = 'thestreet';",
    "textAfterTable": "Markets DOW 17,761.28 +15.30 0.09% S&P 500 2,112.74 +4.11 0.19% NASDAQ 5,147.3310 +18.5460 0.36%",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}